nVerses Capital’s Idexx Laboratories IDXX Stock Holding History

nVerses Capital’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-100	Closed	-$48.7K	–	1185
2024 Q2	$48.7K	Buy	+100	New	+$50.2K	0.03%	600

Other funds holding IDXX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

nVerses Capital's IDXX Position: Q3 2024 in Review

nVerses Capital sold out of Idexx Laboratories (IDXX) in Q3 2024, closing a stake of 100 shares — an estimated $48.7K sold.

nVerses Capital first reported a position in IDXX in Q2 2024 and held it in 1 quarter. The position peaked at $48.7K in Q2 2024. 1,115 funds tracked by Wall St. Rank hold IDXX as of Q3 2024.

nVerses Capital reported no remaining Idexx Laboratories position as of Q3 2024 after selling out during the quarter.
nVerses Capital sold 100 Idexx Laboratories shares in Q3 2024, an estimated $48.7K.
nVerses Capital first reported a position in Idexx Laboratories in Q2 2024 and held it in 1 quarter.
nVerses Capital's Idexx Laboratories position peaked at $48.7K in Q2 2024.
1,115 funds tracked by Wall St. Rank held Idexx Laboratories as of Q3 2024.

Based on nVerses Capital's 13F filing for Q3 2024, filed 16 Oct 2024.